Cytokinetics, Inc. CYTK Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Apr 25, 2024 (filed on Apr 25, 2024)

Insider Name:

Henderson John T

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,562

Price:

$64.54
Apr 12, 2024 (filed on Apr 15, 2024)

Insider Name:

Malik Fady Ibraham

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

-150

Price:

--
Apr 09, 2024 (filed on Apr 09, 2024)

Insider Name:

Malik Fady Ibraham

Ownership Type:

Direct Ownership

Securities:

Non-Qualified Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-28,605

Price:

--
Apr 09, 2024 (filed on Apr 09, 2024)

Insider Name:

Malik Fady Ibraham

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,000

Price:

$74.32
Apr 09, 2024 (filed on Apr 09, 2024)

Insider Name:

Malik Fady Ibraham

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-28,605

Price:

$74.31
Apr 09, 2024 (filed on Apr 09, 2024)

Insider Name:

Malik Fady Ibraham

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

28,605

Price:

$6.67
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Wong Robert

Ownership Type:

Direct Ownership

Securities:

Non-Qualified Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

3,308

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Wong Robert

Ownership Type:

Direct Ownership

Securities:

Incentive Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,403

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Wong Robert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

4,079

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Callos Andrew

Ownership Type:

Direct Ownership

Securities:

Incentive Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,224

Price:

--

Filings by filing date

Apr 25, 2024 (filed on Apr 25, 2024)

Insider Name:

Henderson John T

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,562

Price:

$64.54
Apr 12, 2024 (filed on Apr 15, 2024)

Insider Name:

Malik Fady Ibraham

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

-150

Price:

--
Apr 09, 2024 (filed on Apr 09, 2024)

Insider Name:

Malik Fady Ibraham

Ownership Type:

Direct Ownership

Securities:

Non-Qualified Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-28,605

Price:

--
Apr 09, 2024 (filed on Apr 09, 2024)

Insider Name:

Malik Fady Ibraham

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,000

Price:

$74.32
Apr 09, 2024 (filed on Apr 09, 2024)

Insider Name:

Malik Fady Ibraham

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-28,605

Price:

$74.31
Apr 09, 2024 (filed on Apr 09, 2024)

Insider Name:

Malik Fady Ibraham

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

28,605

Price:

$6.67
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Wong Robert

Ownership Type:

Direct Ownership

Securities:

Non-Qualified Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

3,308

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Wong Robert

Ownership Type:

Direct Ownership

Securities:

Incentive Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,403

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Wong Robert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

4,079

Price:

--
Mar 14, 2024 (filed on Mar 18, 2024)

Insider Name:

Callos Andrew

Ownership Type:

Direct Ownership

Securities:

Incentive Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,224

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	350 Oyster Point Boulevard SOUTH SAN FRANCISCO CA 94080
Tel:	1-650-6243060
Website:	https://cytokinetics.com
IR:	See website

Key People

Robert I. Blum President, Chief Executive Officer, Director	Andrew M. Callos Executive Vice President, Chief Commercial Officer	Fady Ibraham Malik Executive Vice President - Research and Development
Robert Wong Chief Accounting Officer, Vice President

Business Overview

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.

Financial Overview

For the fiscal year ended 31 December 2023, Cytokinetics, Inc. revenues decreased 92% to $7.5M. Net loss increased 35% to $526.2M. Revenues reflect Realization of revenue participation rig decrease from $87M to $0K, Revenue Sales of Goods & Serv decrease of 39% to $4M. Higher net loss reflects Research and development increase of 34% to $298M (expense), Stock Based Compensation in R&D increase of 68% to $32.1M (expense).

Employees:	423 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$6,992M as of Dec 31, 2023
Annual revenue (TTM):	$7.53M as of Dec 31, 2023
EBITDA (TTM):	-$484.31M as of Dec 31, 2023
Net annual income (TTM):	-$526.24M as of Dec 31, 2023
Free cash flow (TTM):	-$415.75M as of Dec 31, 2023
Net Debt Last Fiscal Year:	$3.82M as of Dec 31, 2023
Shares outstanding:	104,576,087 as of Mar 26, 2024
Index Membership:	S&P 400 Mid Cap
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization